Results 81 to 90 of about 28,326 (256)

Integrating ctDNA testing for EGFR analysis in advanced non-small cell lung cancer: strategies for clinical laboratories

Advances in Laboratory Medicine
Epidermal growth factor receptor gene (EGFR) molecular testing is essential for guiding targeted therapies in patients with advanced non-small cell lung cancer (NSCLC). Between 15 and 40 % of patients with NSCLC carry mutations in EGFR that are sensitive
Fernández-Galán Esther, Puig-Butillé Joan Anton   +1 more
doaj   +1 more source

Intra-Tumor Heterogeneity of Colorectal Cancer Necessitates the Multi-Regional Sequencing for Comprehensive Mutational Profiling

Cancer Management and Research, 2021
Shaohua Guo,1,2,* Yumeng Ye,3,* Xinyi Liu,4 Yuan Gong,5 Mingyan Xu,4 Lele Song,4,6 Hongyi Liu1 1Department of General Surgery, The First Medical Center of the Chinese PLA General Hospital, Beijing, People’s Republic of China; 2Department of ...
Guo S, Ye Y, Liu X, Gong Y, Xu M, Song L, Liu H   +6 more
doaj  

Mapping the breast cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking [PDF]

, 2020
Circulating tumour DNA (ctDNA) allows tracking of the evolution of human cancers at high resolution, overcoming many limitations of tissue biopsies.
Zapata, Luis, Tari, Haider, Nichol, Daniel, Sottoriva, Andrea, Cresswell, George D, Zapata, L, Ashworth, A, Magnani, L, Barry, Peter, Spiteri, Inmaculada, Schiavon, G, Barry, P, Sottoriva, A, Heide, T, Heide, Timon, Nichol, D, Tari, H, Magnani, Luca, Cresswell, GD, Ashworth, Alan, Maley, Carlo C, Schiavon, Gaia, Spiteri, I, Maley, CC   +23 more
core   +1 more source

Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review

Head &Neck, EarlyView.
ABSTRACT Objective To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. Summary Background Data Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients ...
Nicholas Brian Shannon, Bruce Ashford
wiley   +1 more source

La integración de la prueba de ctDNA en el análisis de EGFR en el carcinoma pulmonar no microcítico: estrategias para el laboratorio clínico

Advances in Laboratory Medicine
El análisis molecular del gen receptor del factor de crecimiento epidérmico (EGFR) resulta fundamental a la hora de seleccionar una terapia dirigida para el carcinoma pulmonar no microcítico avanzado (CPNM).
Fernández-Galán Esther, Puig-Butillé Joan Anton   +1 more
doaj   +1 more source

Sizing and concentration analysis of cfDNA using Biabooster technology: Results from a prospective plasma‐based collection of 77 patients with locally advanced unresectable esophageal cancer

International Journal of Cancer, EarlyView.
What's New? This study introduces a novel approach for detecting locally advanced esophageal carcinoma using cell‐free DNA (cfDNA) analysis through a highly sensitive fragmentome assay. Unlike traditional sequencing‐based methods that are limited by the absence of specific mutations in esophageal tumors, our method offers an alternative by quantifying ...
Anouchka Modesto, Sophie Gibert, Caroline Delmas, David Tougeron, Amaury Paumier, Alexandre Taillez, Samuel Le Sourd, Delphine Argo Leignel, Philippe Ronchin, Ariane Darut Jouve, Véronique Vendrely, Olivier Riou, Jérôme Martin‐Babau, Thomas Leroy, Laurent Quéro, Naïma Hanoun, Pierre Cordelier, Veronica Pezzella, Jean Pierre Delord, Rosine Guimbaud, Elizabeth Moyal, Catherine Seva   +21 more
wiley   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

International Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold, Gloria Baumann, Victoria Luise Simone Wieland, Nicolas Carl, Luisa Vivienne Renner, Alexander Studier‐Fischer, Hanna Menold, Stefanie Zschäbitz, Frederik Wessels, Niklas Westhoff, Maurice Stephan Michel, Karl‐Friedrich Kowalewski, Caelán Max Haney‐Aubert   +12 more
wiley   +1 more source

A Serum lncRNA Signature Determines Oncogenic YAP Activity in Cancer Patients

International Journal of Cancer, EarlyView.
Long non‐coding RNAs (lncRNAs) signatures are promising cancer biomarkers, since their dysregulation in tumors is reflected in body fluids. In this study, next‐generation sequencing, bioinformatics, and gene expression data were combined to investigate an lncRNA signature linked specifically to the cancer‐promoting YAP in several cancer types ...
Fabian Rose, Nada El‐Ekiaby, Lilija Wehling, Sofia Maria Elisabeth Weiler, Jennifer Schmitt, Marcell Tóth, Fabiola Pedrini, Amruta Damle‐Vartak, Carsten Sticht, Rossella Pellegrino, Injie Omar Fawzy, Merna Hatem Mohamed Hamad, Mohamed Negm, Dina Omar, Hossam Eldeen Soliman, Gamal Esmat, Thomas Longerich, Thomas Illig, Bruno Christian Köhler, Anna Saborowski, Heike Bantel, Arndt Vogel, Peter Schirmacher, Ahmed Ihab Abdelaziz, Kai Breuhahn   +24 more
wiley   +1 more source

Circulating tumor DNA in patients with cancer: insights from clinical laboratory

Advances in Laboratory Medicine
Blood-based circulating tumor DNA (ctDNA) analysis has emerged as a highly relevant non-invasive method for molecular profiling of solid tumors, offering valuable information about the genetic landscape of cancer.
Illana Francisco J., Fernández-Galán Esther, Muñoz-Bravo José Luis, Valiña Amado Laura, García Martín Carme, González-Fernández Carolina, Miró-Cañís Sílvia, Trapé Jaume, Martínez-Peinado Antonio, Filella Xavier, González Alvaro, Sánchez Antonio Barco, Díaz-Lagares Angel,   +13 more
doaj   +1 more source

Predictive Biomarkers in Metastatic Colorectal Cancer Patients Treated With Bevacizumab: A Turkish Oncology Group (TOG) Study

International Journal of Cancer, EarlyView.
Bevacizumab added to systemic chemotherapy remains a cornerstone of metastatic colorectal cancer treatment, but its effectiveness is variable. Tumors can bypass the VEGF blockade by activating other pro‐angiogenic pathways, hampering the identification of predictive biomarkers.
Büsra Akay Hacan, Fatma Gizem Sonugür, Müge Öçal, Cansu Babahan, Samira Abgarmi, Ülkü Yalçıntaş Arslan, Mehmet Ali Şendur, Ahmet Demirkazık, Güngör Utkan, Hakan Akbulut   +9 more
wiley   +1 more source